Residue 67 in the DR β1*0101 and DR β1*0103 chains strongly influences antigen presentation and DR-peptide molecular complex conformation

Tissue Antigens

Volumn 51, Issue 1, 1998, Pages 10-19

  L'Faqihi, F E ^a   Praud, C ^a   Yassine Diab, B ^a   Enault, G ^a   Lakhdar Ghazal, F ^a   De Preval C ^a   Coppin, H ^a  

^a CHU PURPAN   (France)

Author keywords

Antigen presentation; Antigen specific T cell response; MHC polymorphism; Molecular conformation

Indexed keywords

HLA DR ANTIGEN; PHENYLALANINE; GLUTAMINE; HLA DR1 ANTIGEN; ISOLEUCINE; LEUCINE; PEPTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; COMPLEX FORMATION; CONFORMATION; CONTROLLED STUDY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOLECULAR MODEL; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; ADULT; ANIMAL; BINDING SITE; CELL CLONE; CELL CULTURE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CYTOLOGY; GENETICS; IMMUNOLOGY; MOUSE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ADULT; ANIMALS; ANTIGEN PRESENTATION; BINDING SITES; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELLS, CULTURED; CLONE CELLS; GLUTAMINE; HLA-DR1 ANTIGEN; HUMANS; ISOLEUCINE; LEUCINE; MICE; MODELS, MOLECULAR; PEPTIDES; PHENYLALANINE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0031594214     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb02942.x     Document Type: Article

References (31)

1. Busch R, Hill CM, Hayball JD, Lamb JR, Rothbard JB. Effect of natural polymorphism at residue 86 of the HLA-DRβ chain on peptide binding. J Immunol 1991: 147: 1292.
2. Krieger JI, Karr RW, Grey HM et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T-cell recognition. J Immunol 1991: 146: 2331.
3. Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993: 364: 33.
4. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994: 368: 215.
5. Panina-Bordignon P, Fu XT, Lanzavecchia A, Karr RW. Identification of HLA-DR α chain residues critical for binding of the toxic shock syndrome toxin superantigen. J Exp Med 1992: 176: 1779.
6. Boehncke WH, Takeshita T, Sadegh-Nasseri S, Racciopi L, Berzofsky JA, Germain RN. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T-cell recognition. J Immunol 1933: 150: 331.
7. Karr RW, Yu WY, Watts R, Evans KS, Celis E. The role of polymorphic HLA-DRβ chain residues in presentation of viral antigens to T cells. J Exp Med 1990: 172: 273.
8. Karr RW, Panina-Bordignon P, Yu WY, Lanzavecchia A. Antigen-specific T cells with monogamous or promiscuous restriction patterns are sensitive to different HLA-DRβ chain substitutions. J Immunol 1991: 146: 4242.
9. Coppin HL, Villedieu P, Thomsen M, Giraud P, Cambon-Thomsen A, Charron D. HLA-D/DR-BON: a new biochemically and cellularly defined polymorphism indistinguishable by RFLP from DR1. Immunogenetics 1987: 25: 130.
10. Coppin HL, Avoustin P, Fabron J. Evolution of the HLA-DR1 gene family. Structural and functional analysis of the new allele "DR-BON". J Immunol 1990: 144: 984.
11. Coppin HL, Carmichael P, Lombardi G et al. Position 71 in the α helix of the DRβ domain is predicted to influence peptide binding and plays a central role in allorecognition. Eur J Immunol 1993: 23: 349.
12. McKinney JS, Fu XT, Swearingen C, Klohe E, Karr RW. Individual effects of the DR11-variable β-chain residues 67, 71, and 86 upon DR(α, β1*1101)-restricted, peptide-specific T-cell proliferation. J Immunol 1994: 153: 5564.
13. Olson RR, Reuter JJ, McNicholl J et al. Acidic residues in the DRβ chain third hypervariable region are required for stimulation of a DR(α, β1*0402)-restricted T-cell clone. Hum Immunol 1994: 41: 193.
14. Herman A, Parham P, Weissman SM, Engelhard VH. Recognition by xenogenic cytotoxic T lymphocytes of cells expressing HLA-A2 or HLA-B7 after DNA mediated gene transfer. Proc Natl Acad Sci U S A 1983: 80: 5056.
15. Praud C, Jurcevic S, L'Faqihi FE, Guiraud M, de Préval C, Thomsen M. Promiscuous and specific binding of HIV peptides to HLA-DR1 and DR103: impact on T-cell repertoire of non-immunized individuals. Hum Immunol 1994: 41: 1.
16. Buus S, Sette A, Colon SM, Jenis DM, Grey HM. Isolation and characterization of antigen-Ia complexes involved in T-cell recognition. Cell 1986: 47: 1071.
17. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program of macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983: 4: 187.
18. Dunbrack RL, Karplus M. Backbone-dependent rotamer library for proteins. Application to side chain prediction. J Mol Biol 1993: 230 : 543.
19. Zeliszewski D, Golvano JJ, Gaudebout P et al. Implication of HLA-DR residues at position 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320. J Immunol 1993: 151: 6237.
20. Fu XT, Bono CP, Woulfe SL et al. Pocket 4 of the HLA-DR(α, β1*0401) molecule is a major determinant of T-cell recognition of peptide. J Exp Med 1995: 181: 915.
21. Cambon-Thomsen A, Thomsen M, Abbal M, Sommer E, Calot M, Ohayon E. A new HLA-D specificity associated with DR blank: D-BON. Tissue Antigens 1986: 27: 256.
22. Ronchese F, Schwartz RH, Germain RN. Functionally distinct subsites on a class II major histocompatibility complex molecule. Nature 1987: 329: 254.
23. Blank U, Boitel B, Mège D, Ermonval M, Acuto O. Analysis of tetanus toxin peptide/ DR recognition by human T-cell receptors reconstituted into a murine T-cell hybridoma. Eur J Immunol 1993: 23: 3057.
24. Olson RR, De Magistris T, Di Tommaso A, Karr RW. Mutations in the third, but not the first or second, hypervariable regions of DRβ(1*0101) eliminate DR1-restricted recognition of a pertussis toxin peptide. J Immunol 1992: 148: 2703.
25. Lombardi G, Barber L, Sidhu S, Batchelor JR, Lechler RI. The specificity of alloreactive T cells is determined by MHC polymorphisms which contact the T-cell receptor and which contact peptide binding. Int Immunol 1991: 3: 769.
26. Jurcevic S, Travers PJ, Hills A, Agrewala JN, Moreno C, Ivanyi J. Distinct conformations of a peptide bound to HLA-DR1 or DRB5*0101 suggested by molecular modelling. Int Immunol 1996: 8: 1807.
27. Pease LR, Horton RM, Pullen JK et al. Amino acid changes in the peptide-binding site have structural consequences at the surface of class I glycoproteins. J Immunol 1993: 150: 3375.
28. b. Int Immunol 1994: 6: 1037.
29. Madden DR, Garboczi, DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993: 75: 693.
30. Garcia KC, Degano M, Stanfield RL et al. An αβ T-cell receptor structure at 2.5 Å and its orientation in the TcR-MHC complex. Science 1996: 274 : 209.
31. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC, Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996: 384: 134.